ArticleNature2019
α-Ketoglutarate links p53 to cell fate during tumour suppression.
Abstract read
In one paragraph
Article in Nature, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 211 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
211citing papers in PubMed, 1 pooled it
12.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
211 citing papers in PubMed, 1 synthesis or guideline pooled it, 292 citations in OpenAlex.
- Aberrant Energy Metabolism in Tumors and Potential Therapeutic Targets.Genes, chromosomes & cancer · 2024Pooled it
- Diet-Induced Phospholipid Remodeling Dictates Ferroptosis Sensitivity and Tumorigenesis in the Pancreas.Cancer discovery · 2026Article
- α-KG conformationally stabilizes nuclear GLUD1-SNAIL complex to fuel trans-endothelial migration in metastasis.Nature communications · 2026Article
- Article
- A transcriptional biosensor reveals mechanisms of α-ketoglutarate signaling to chromatin.Science (New York, N.Y.) · 2026Article
- Nuclear adenosine metabolism defines a metabolic vulnerability unmasked by TP53 loss.bioRxiv : the preprint server for biology · 2026Article
- Functional role of a structural water in the elevator domain of dicarboxylate transporter VcINDY.PNAS nexus · 2026Article
- Targeting mitochondrial α-ketoglutarate sequestration disables dual oncogenic drivers and metabolic adaptability in pancreatic ductal adenocarcinoma.Cell death & disease · 2026Article
- Choline metabolism drives metastasis in BRCA1-deficient ovarian cancers by activating FAM3C.Nature communications · 2026Article
- OGDH primes macrophage for M1-like polarization and ferroptosis in sepsis associated acute lung injury.Respiratory research · 2026Article
- Article
- HER2-driven mammary tumorigenesis enhances bioenergetics despite reductions in mitochondrial content.eLife · 2026Article
- Article
- Gut microbiota and pancreatic cancer: tumorigenesis, progression, and clinical applications.Cancer biology & medicine · 2026Review
- The crosstalk between epigenetics and metabolism in the malignant cell.Discover oncology · 2026Review
- Aspartate availability drives differential engagement of the malate-aspartate shuttle.Molecular cell · 2026Article
- Molecular and cellular landscapes of the immune microenvironment and multiomic biomarker-sets in platinum-resistant recurrent ovarian cancers.Journal of ovarian research · 2026Review
- Cholesterol Metabolism-related Characteristics Predict Therapeutic Response and Survival in Esophageal Cancer.Journal of advanced research · 2026Article
- Alpha-ketoglutarate restores oral epithelial homeostasis via FOXM1-mediated cell cycle regulation.Science China. Life sciences · 2026Article
- α-Ketoglutarate dictates AMPK protein synthesis for energy sensing in human cancers.Nature chemical biology · 2026Article
151 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on bySuppressed fate.2019
Authors and funding
14 authors at 5 institutions in 1 country.
John P Morris *Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jossie J Yashinskie *Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Richard KocheCenter for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Rohit ChandwaniDepartment of Surgery, Weill Cornell Medical College, New York, NY, USA.
Sha TianCancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Chi-Chao ChenCancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Timour BaslanCancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Zoran S MarinkovicDepartment of Biology, Center for Genomics and Systems Biology, New York University, New York, NY, USA.
Francisco J Sánchez-RiveraCancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Steven D LeachRubinstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Carlos Carmona-FontaineDepartment of Biology, Center for Genomics and Systems Biology, New York University, New York, NY, USA.
Craig B ThompsonCancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Lydia W S FinleyCell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. finleyl@mskcc.org.
Scott W LoweCancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. lowes@mskcc.org.
Memorial Sloan Kettering Cancer Center · USNew York University · USCornell University · USDartmouth College · USJanelia Research Campus · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MVIRAL TRANSACTIVATIONP01CA013106 · NCI · COLD SPRING HARBOR LABORATORY · PI William Richard McCombie · 1985 to 2026
$116.8MScientific ReagentsP01CA087497 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI PRIVES, CAROL · 2000 to 2021
$35.4MTraining Program in Developmental BiologyT32HD060600 · NICHD · WEILL MEDICAL COLL OF CORNELL UNIV · PI BAO, ZHIRONG, STUHLMANN, HEIDI · 2010 to 2024
$3.5MTranslational Research in Oncology Training ProgramT32CA160001 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2011 to 2020
$2.0MComprehensive genetic dissection of druggable KRAS targetsR01CA204228 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LEACH, STEVEN D · 2016 to 2020
$1.9MUsing extracellular metabolites to understand and revert protumoral effects of Tumor-Associated MacrophagesR00CA191021 · NCI · NEW YORK UNIVERSITY · PI CARMONA-FONTAINE, CARLOS · 2017 to 2019
$747kHoward Hughes Medical InstituteNCI NIH HHS P01 CA013106NCI NIH HHS P01 CA087497NCI NIH HHS P30 CA008748NCI NIH HHS R00 CA191021NCI NIH HHS R01 CA204228NCI NIH HHS T32 CA160001NICHD NIH HHS T32 HD060600
Abstract
The tumour suppressor TP53 is mutated in the majority of human cancers, and in over 70% of pancreatic ductal adenocarcinoma (PDAC)
Indexed as
Carcinoma, Pancreatic DuctalPancreatic NeoplasmsAnimalsCell DifferentiationCell Line, TumorChromatin Assembly and DisassemblyDisease Models, AnimalGene Expression Regulation, NeoplasticKetoglutaric AcidsMiceProtein BindingSuccinic AcidTranscriptional ActivationTumor Suppressor Protein p53Ketoglutaric AcidsSuccinic AcidTrp53 protein, mouseTumor Suppressor Protein p53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.